including Eli Lilly’s $3.2 billion purchase of Morphic Holding in July and Vertex’s $4.9 billion buy of Alpine Immune Sciences.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » First, let's consider how Eli Lilly's newest products will affect its performance in the ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,100.00. The company’s shares closed yesterday at $911.06.

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.

We recently compiled a list of the Top 10 Stocks to Buy According to Lone Pine Capital. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

Finally, Truist Financial upped their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. Get Eli ...

Teladoc and LifeMD are partnering with drugmaker Eli Lilly to offer the weight loss drug Zepbound directly to self-paying patients. The two telehealth companies said Thursday they’re working ...

Citi analyst Geoff Meacham reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,190.00. The company’s shares closed last Friday at $873.68.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...